

# Emiel van der Kouwe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/991831/publications.pdf>

Version: 2024-02-01

10  
papers

275  
citations

1307594

7  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

562  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
3	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	1.4	12
4	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021, 138, 1331-1344.	1.4	19
5	<i>IL2RA</i> Promotes Aggressiveness and Stem Cell-Related Properties of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 4527-4539.	0.9	12
6	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
7	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
8	RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 350.	4.1	17
9	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
10	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. <i>Blood</i> , 2017, 130, 855-855.	1.4	0